MaaT013
Sponsors
MaaT PHARMA, Assistance Publique Hopitaux De Paris, MaaT Pharma, Assistance Publique - Hôpitaux de Paris
Conditions
Acute Graft Versus Host Disease in IntestineGastrointestinal Acute Graft-versus-Host Disease (GI-aGvHD)MelanomaSteroid Refractory GVHDTreatment of acute graft-versus host disease (aGvHD) to the gastrointestinal (GI) tract of patients who are resistant or intolerant to ruxolitinib.
Phase 2
Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma
CompletedNCT04988841
Start: 2022-01-20End: 2025-04-22Updated: 2025-08-28
PICASSO. Prospective randomIzed clinical trial assessing the tolerance and clinical benefit of feCAl tranSplantation in patientS with melanOma treated with CTLA-4 and PD-1 inhibitors
CompletedCTIS2024-516100-42-00
Start: 2022-03-18End: 2025-04-22Target: 70Updated: 2025-07-10
A Multicentre, Open-Label Study Evaluating the Safety, Tolerability and Efficacy of MaaT013 in Ruxolitinib-Refractory or Intolerant Paediatric and Adolescent participants with Gastrointestinal Acute Graft-versus-Host Disease
Not yet recruitingCTIS2025-524302-15-00
Target: 6Updated: 2026-04-17
Phase 3
MaaT013 As Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients
Active, not recruitingNCT04769895
Start: 2022-03-25End: 2025-11-30Updated: 2024-10-17
EvAluation of the efficacy of MaaT013 as salvage theRapy in acute GVHD patiEntS with gastrointestinal involvement, refractory to ruxolitinib; a multi-center open-label phase III trial.
CompletedCTIS2024-513023-17-00
Start: 2022-01-12End: 2025-09-24Target: 73Updated: 2025-02-24